vs
CNO Financial Group, Inc.（CNO）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
CNO Financial Group, Inc.的季度营收约是Royalty Pharma plc的1.8倍（$1.1B vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 8.8%，领先25.6%），Royalty Pharma plc同比增速更快（4.8% vs 4.2%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -0.6%）
CNO金融集团是总部位于美国印第安纳州卡梅尔的金融服务控股公司，前身为康塞科公司。集团旗下保险子公司为美国超400万客户提供人寿保险、年金和补充健康保险产品，通过独立代理人、专属代理人，以及电视广告、直邮等直销触达用户。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CNO vs RPRX — 直观对比
营收规模更大
CNO
是对方的1.8倍
$622.0M
营收增速更快
RPRX
高出0.6%
4.2%
净利率更高
RPRX
高出25.6%
8.8%
两年增速更快
RPRX
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $622.0M |
| 净利润 | $100.7M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 15.2% | 62.4% |
| 净利率 | 8.8% | 34.4% |
| 营收同比 | 4.2% | 4.8% |
| 净利润同比 | -39.4% | 2.9% |
| 每股收益（稀释后） | $1.02 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CNORPRX
| Q4 25 | $1.1B | $622.0M | ||
| Q3 25 | $1.2B | $609.3M | ||
| Q2 25 | $1.2B | $578.7M | ||
| Q1 25 | $1.0B | $568.2M | ||
| Q4 24 | $1.1B | $593.6M | ||
| Q3 24 | $1.1B | $564.7M | ||
| Q2 24 | $1.1B | $537.3M | ||
| Q1 24 | $1.2B | $568.0M |
净利润CNORPRX
| Q4 25 | $100.7M | $214.2M | ||
| Q3 25 | $23.1M | $288.2M | ||
| Q2 25 | $91.8M | $30.2M | ||
| Q1 25 | $13.7M | $238.3M | ||
| Q4 24 | $166.1M | $208.2M | ||
| Q3 24 | $9.3M | $544.0M | ||
| Q2 24 | $116.3M | $102.0M | ||
| Q1 24 | $112.3M | $4.8M |
营业利润率CNORPRX
| Q4 25 | 15.2% | 62.4% | ||
| Q3 25 | 13.7% | 70.1% | ||
| Q2 25 | 9.8% | 36.3% | ||
| Q1 25 | 10.4% | 94.0% | ||
| Q4 24 | 15.8% | 60.9% | ||
| Q3 24 | 13.6% | — | ||
| Q2 24 | 13.9% | 50.2% | ||
| Q1 24 | 6.5% | -13.0% |
净利率CNORPRX
| Q4 25 | 8.8% | 34.4% | ||
| Q3 25 | 1.9% | 47.3% | ||
| Q2 25 | 8.0% | 5.2% | ||
| Q1 25 | 1.4% | 41.9% | ||
| Q4 24 | 15.1% | 35.1% | ||
| Q3 24 | 0.8% | 96.3% | ||
| Q2 24 | 10.9% | 19.0% | ||
| Q1 24 | 9.7% | 0.8% |
每股收益（稀释后）CNORPRX
| Q4 25 | $1.02 | $0.49 | ||
| Q3 25 | $0.24 | $0.67 | ||
| Q2 25 | $0.91 | $0.07 | ||
| Q1 25 | $0.13 | $0.55 | ||
| Q4 24 | $1.58 | $0.46 | ||
| Q3 24 | $0.09 | $1.21 | ||
| Q2 24 | $1.06 | $0.23 | ||
| Q1 24 | $1.01 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $2.6B | $9.7B |
| 总资产 | $38.8B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CNORPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务CNORPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益CNORPRX
| Q4 25 | $2.6B | $9.7B | ||
| Q3 25 | $2.6B | $9.6B | ||
| Q2 25 | $2.5B | $9.5B | ||
| Q1 25 | $2.5B | $9.8B | ||
| Q4 24 | $2.5B | $10.3B | ||
| Q3 24 | $2.7B | $10.3B | ||
| Q2 24 | $2.4B | $9.8B | ||
| Q1 24 | $2.4B | $9.9B |
总资产CNORPRX
| Q4 25 | $38.8B | $19.6B | ||
| Q3 25 | $38.3B | $19.3B | ||
| Q2 25 | $37.3B | $18.3B | ||
| Q1 25 | $37.4B | $17.6B | ||
| Q4 24 | $37.9B | $18.2B | ||
| Q3 24 | $37.6B | $18.0B | ||
| Q2 24 | $36.3B | $17.7B | ||
| Q1 24 | $34.9B | $16.1B |
负债/权益比CNORPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $195.7M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.94× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CNORPRX
| Q4 25 | $195.7M | $827.1M | ||
| Q3 25 | $197.8M | $702.6M | ||
| Q2 25 | $145.5M | $364.0M | ||
| Q1 25 | $136.7M | $596.1M | ||
| Q4 24 | $191.0M | $742.5M | ||
| Q3 24 | $231.2M | $703.6M | ||
| Q2 24 | $110.9M | $658.2M | ||
| Q1 24 | $94.6M | $664.6M |
现金转化率CNORPRX
| Q4 25 | 1.94× | 3.86× | ||
| Q3 25 | 8.56× | 2.44× | ||
| Q2 25 | 1.58× | 12.06× | ||
| Q1 25 | 9.98× | 2.50× | ||
| Q4 24 | 1.15× | 3.57× | ||
| Q3 24 | 24.86× | 1.29× | ||
| Q2 24 | 0.95× | 6.45× | ||
| Q1 24 | 0.84× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CNO
| Health Insurance Product Line | $496.4M | 43% |
| Life Insurance Segment | $268.8M | 24% |
| Other | $207.2M | 18% |
| Life And Annuity Insurance Product Line | $170.7M | 15% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
